Abstract :
Clinical decision-makers face major challenges in understanding the advantages and limitations of germline sequencing tests. Robust sequencing technologies characterized by high-accuracy reads are necessary. With these technologies, the full potential of clinical sequencing assays to detect all clinically important variants can be reached.